CFTR and congenital rubella syndrome: Combining the CFTR-potentiator ivacaftor with the CFTR-corrector lumacaftor has shown positive results on lung function, growth, and reduced the risk of pulmonary exacerbations [15] but no effects on CRS have been reported.